National and Kapodistrian University of Athens
Μοριακή σταδιοποίηση του καρκίνου του πνεύμονα
Abstract
dc:descriptionDisseminated disease is the primary cause of mortality among lung cancer patients. Recent research data indicate that cancer cells disseminate to secondary sites very early during tumour development, and subsequently lead to cancer evolution. Cancer cells that detach from the site of the primary tumor, are called circulating tumor cells (CTC). These cells disseminate via the blood circulation and form metastasis in coastal or distal sites, without been detected by current imaging techniques. CTC detection in lung cancer patients΄ peripheral blood, is a promising tool for the detection of residual cancer disease. Τhe presence of CTC in bloodstream is associated with the development of systemic disease or high risk of recurrence. Furthermore CTC count is also particularly useful for monitoring response to therapy. Clinical utility of such monitoring of therapeutic effectiveness lies in the opportunity to check its success or to rapidly terminate ineffective treatment in order to prevent side effects and unnecessary costs. Early diagnosis, accurate staging and the appropriate curative treatment, determine the good prognosis of the disease. A strategy for the determination of CTC as a prognostic or diagnostic biomarkers, could help physicians make treatment decisions that might lengthen a person’s life expectancy after their cancer diagnosis. Current Clinical Oncology guidelines do not yet support the individual routine use of CTC assays in clinical use, mainly due to the lack of standardized protocols. The aim of this study was the establishment of a non-invasive, simple, short term and sensitive method, which would reveal the presence of CTC in peripheral blood of lung cancer patients. This test doesn’t detect LC but may improve lung cancer staging process. Multiplex polymerase chain reaction predominates over simple PCR due to simultaneous amplification of gene specific primers in a single reaction. The specific biomarkers used in the study, were parathyroid hormone related protein (PTHrP), cytokeratin 19 (CK19), lung-specific X protein (LUNX) and gastrin releasing propeptide (preproGRP). GAPDH was used as internal control of the experimental process. The application of this method on cancer cell lines and healthy donors’ peripheral blood, determined the sensitivity and specificity of the assay. The decision to coamplify more than one biomarker, increases the sensitivity of the assay. Moreover, statistical analysis of the results, correlated the detection of CTC with residual cancer disease and specific sites of metastasis formation. The aforementioned method, supplements the current imaging and diagnostic techniques, but cannot substitute them.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Katseli, Anastasia
- Κατσέλη, Αναστασία
Subjects
dc:subject × 18- Καρκίνος του πνεύμονα
- Μοριακή σταδιοποίηση
- Πολλαπλή αλυσιδωτή αντίδραση πολυμεράσης
- Περιφερικό αίμα
- Lung cancer
- Molecular staging
- Multiple polymerase crain reaction
- Peripheral blood
- CK19
- PTHrP
- LUNX
- prepro GRP
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Ιατρική Βιοτεχνολογία
- Medical and Health Sciences
- Clinical Medicine
- Medical Biotechnology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/38505